Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus

Sanofi’s Lantus is already facing off against generic competition from Eli Lilly and Boehringer’s Basaglar, but now Mylan is adding to the pressure by prevailing in a patent challenge at the U.S. Patent and Trademark Office.